NCT04813354View on ClinicalTrials.gov

A Comparison of Critical Errors, Overall Errors, Training/Teaching Time, and Preference Attributes of the ELLIPTA Versus BREEZHALER Dry Powder Inhalers (DPIs) in Adult Participants With Asthma

PHASE4CompletedINTERVENTIONAL
Enrollment

114

Participants

Timeline

Start Date

April 14, 2021

Primary Completion Date

July 8, 2021

Study Completion Date

July 8, 2021

Conditions
Asthma
Interventions
DEVICE

ELLIPTA

"* ELLIPTA followed by BREEZHALER/ Preference Questionnaire version 1~* ELLIPTA followed by BREEZHALER/ Preference Questionnaire version 2~* BREEZHALER followed by ELLIPTA/ Preference Questionnaire version 1~* BREEZHALER followed by ELLIPTA/ Preference Questionnaire version 2"

DEVICE

BREEZHALER

"* ELLIPTA followed by BREEZHALER/ Preference Questionnaire version 1~* ELLIPTA followed by BREEZHALER/ Preference Questionnaire version 2~* BREEZHALER followed by ELLIPTA/ Preference Questionnaire version 1~* BREEZHALER followed by ELLIPTA/ Preference Questionnaire version 2"

Trial Locations (3)

7512 KZ

GSK Investigational Site, Enschede

7442 LS

GSK Investigational Site, Nijverdal

3051 GV

GSK Investigational Site, Rotterdam

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT04813354 - A Comparison of Critical Errors, Overall Errors, Training/Teaching Time, and Preference Attributes of the ELLIPTA Versus BREEZHALER Dry Powder Inhalers (DPIs) in Adult Participants With Asthma | Biotech Hunter | Biotech Hunter